May 06, 2026
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer's Disease
Apr 30, 2026
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
Apr 24, 2026
Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy
Apr 23, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
Apr 21, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
Apr 16, 2026
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
Apr 10, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
Apr 02, 2026
Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
Mar 24, 2026
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
Mar 23, 2026
Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
1
2
3
4
5
6
<<
<
>
>>
Copyright © 2021 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.
Privacy
